Reactions to the EU Referendum
24 June 2016 | By Victoria White, Digital Content Producer
The BioIndustry Association and EFPIA have reacted to the news that Britain has voted to leave the European Union (EU)...
List view / Grid view
News
Scientists to progress glioblastoma antibody into clinical trials
23 June 2016 | By Victoria White, Digital Content Producer
With funding amounting to €3.5 million, the molecule, called 6A10, shall undergo the first phase of clinical testing...
EC grants marketing authorisation to Odefsey in HIV
23 June 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation for Gilead’s once-daily single tablet regimen Odefsey for the treatment of HIV-1 infection in certain patients...
First patient treated in fourth dose level NKR-2 Phase I/IIa trial
23 June 2016 | By Victoria White, Digital Content Producer
The study is evaluating Celyad's NKR-2 T-cell therapy using T-cells with NKG2D receptor in patients suffering from AML or multiple myeloma...
GlobalData discuss the consequences of the EU referendum
23 June 2016 | By Victoria White, Digital Content Producer
The company says for the healthcare industry to thrive in the event of the UK leaving the EU, the country would need to adopt a uniquely British approach...
First patient treated in the Phase III ECHO-301 study
23 June 2016 | By Victoria White, Digital Content Producer
ECHO-301 will evaluate Incyte’s epacadostat with Merck’s pembrolizumab as first-line treatment for patients with advanced or metastatic melanoma...
Phase I/II trial of INCAGN1876 in solid tumours starts
22 June 2016 | By Victoria White, Digital Content Producer
The open-label, dose-escalation portion of the trial will evaluate the safety and tolerability of INCAGN1876 in patients with solid tumours...
Rheumatoid arthritis testing market to hit $399.5m by 2022
22 June 2016 | By Victoria White, Digital Content Producer
The rheumatoid arthritis testing market is forecast to rise from $338.5 million in 2015 to $399.5 million by 2022, according to GlobalData...
NICE recommends five drugs to treat four different conditions
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS.
CPhI Pharma Awards 2016 opens with four extra categories
22 June 2016 | By CPhI
CPhI Worldwide, organised by UBM EMEA, announces the opening of the annual CPhI Pharma Awards for 2016...
First patients dosed in Bekinda IBS-D trial
22 June 2016 | By Victoria White, Digital Content Producer
The first patients have been dosed in a Phase II clinical study with RedHill Biopharma’s Bekinda 12 mg for diarrhoea-predominant irritable bowel syndrome...
Infantile spasms selected as 4th target indication for Epidiolex
21 June 2016 | By Victoria White, Digital Content Producer
GW Pharmaceuticals has selected infantile spasms as the fourth target indication for its Epidiolex orphan paediatric epilepsy development programme...
IPF market will grow to $3.2 billion by 2025, says GlobalData
21 June 2016 | By Victoria White, Digital Content Producer
The idiopathic pulmonary fibrosis (IPF) market will rise substantially from just over $900 million in 2015 to $3.2 billion by 2025, according to GlobalData...
First patient treated in Phase I UCART19 trial in paediatric B-ALL
21 June 2016 | By Victoria White, Digital Content Producer
The Phase I study will evaluate the ability of UCART19 to induce molecular remission in paediatric patients with relapsed or refractory CD19 positive B-ALL...
Takeda starts World’s first norovirus vaccine field trial
21 June 2016 | By Victoria White, Digital Content Producer
Takeda has dosed the first subject in a Phase IIb field efficacy trial of its norovirus vaccine candidate, TAK-214...
